- The trend backdrop is active with a 7-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
EWL
GER
Week ended 07 Aug 2026
Weekly Investor Report
Edwards Lifesciences Corporation · Healthcare · Medical Devices
Latest close
77.62 EUR
3.7%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 7.5% above the Trend Line and sits at 71.0% of its 52-week range. The latest completed week returned 3.7%, after a -2.6% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers. The latest news-sentiment score is 55/100. Near-term considerations: volume confirmation is below normal.
Setup score
49
out of 100
Latest Close
77.62 EUR
7 Aug 2026
1W Return
3.7%
latest completed week
4W Return
-2.6%
short-term follow-through
12W Return
10.6%
quarterly tape
Trend Breadth
55.8%
29 of 52 weeks active
Volume Ratio
0.4x
vs 13-week average
- No major top-level risk cluster is currently dominant.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
3.7%
Latest completed week; four-week move -2.6%.
Indicator stack
55/59
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
55/100
17 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 7.5% above the Trend Line and sits at 71.0% of its 52-week range. The latest completed week returned 3.7%, after a -2.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.7212-week average 0.45
12-week confirmation
Trend active7/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.72Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -2.6% over four weeks, 10.6% over 12 weeks, and 16.6% over one year. The current trend has remained active for 7 consecutive weeks.
Performance by holding period
Active trend streak7 weeks
Active weeks in one year29
Trend breadth55.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.71Latest activity-pressure read.
Pressure change-44.1%Four-week change in activity pressure.
Leadership0.97Latest relative-leadership reading.
RS change-89.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength28/100Blend of value, momentum, and quality. Underlying universe rank 73; rank 1 is best.
Value8/100Relative valuation strength. Underlying universe rank 93; rank 1 is best.
Quality83/100Profitability and accounting quality. Underlying universe rank 18; rank 1 is best.
Momentum65/100Medium-term price momentum. Underlying universe rank 36; rank 1 is best.
Growth32/100Revenue and earnings growth. Underlying universe rank 69; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework31/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 40.8x Price divided by trailing earnings.
- Price / sales
- 7.1x Market value relative to trailing revenue.
- EV / EBITDA
- 27.6x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 2.5% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 77.9% Gross profit retained from each unit of revenue.
- Operating margin
- 27.6% Operating profit retained from revenue.
- Free-cash-flow margin
- 17.3% Free cash flow generated from revenue.
- Return on invested capital
- 15.2% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 11.5% Latest one-year revenue growth.
- EPS growth
- -73.9% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 413.7% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 1.9% Net share repurchases relative to market value.
- Shareholder yield
- 1.9% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -1.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment55/100
Weighted news tone is neutral across 17 relevant articles.
4 positive · 13 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-7.6%Distance below the 52-week high.
13-week volatility3.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher15 of 2611 weeks finished lower.
Best week+9.4%Week of 27 Feb.
Worst week-5.4%Week of 10 Apr.
Latest week+3.7%Week of 7 Aug.
Shape of recent returns
Strong gains2
Modest gains13
Flat weeks0
Modest losses8
Sharp losses3
Recent vol3.2%13-week weekly-return volatility.
Base vol3.4%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew2.8% / -2.5%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank53 / 78
Group average1.4%
Trend breadth39.7%
Trend39.7%active weekly trend signals
MD69.2%positive activity pressure
RS34.6%positive relative leadership
Four-week leaders
IndustryDE Medical Devices
4-week rank9 / 12
Group average7.0%
Trend breadth33.3%
Trend33.3%active weekly trend signals
MD75.0%positive activity pressure
RS33.3%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape50/100
Trend, activity pressure, participation, and risk combine to a 50/100 tape read.
Indicator analysis76/100Latest 12-week confirmation: trend 7/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.72; No reversal markers Factors45/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 21; Small Cap Core rank 96 SVQF31/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 259.5 of 375 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment55/100Weighted news tone is neutral across 17 relevant articles.
Edwards Lifesciences Corporation $EW Shares Bought by Royal Bank of Canada Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 77.62 EUR | 3.7% | 72.19 EUR | 70.20 EUR | 0.71 | 0.97 | 251 | On |
| 31 Jul 2026 | 74.88 EUR | -0.1% | 72.04 EUR | 70.16 EUR | 0.92 | 0.16 | 6.4K | On |
| 24 Jul 2026 | 74.98 EUR | -0.6% | 71.94 EUR | 70.14 EUR | 1.11 | 2.41 | 977 | On |
| 17 Jul 2026 | 75.42 EUR | -5.3% | 71.88 EUR | 70.15 EUR | 1.26 | 4.29 | 329 | On |
| 10 Jul 2026 | 79.66 EUR | -3.6% | 71.79 EUR | 70.20 EUR | 1.27 | 9.34 | 201 | On |
| 3 Jul 2026 | 82.62 EUR | 3.2% | 71.51 EUR | 70.22 EUR | 1.14 | 10.60 | 18 | On |
| 26 Jun 2026 | 80.06 EUR | 6.2% | 71.28 EUR | 70.22 EUR | 0.99 | 12.34 | 55 | On |
| 19 Jun 2026 | 75.36 EUR | 3.1% | 71.10 EUR | 70.26 EUR | 0.94 | 4.75 | 24 | Off |
| 12 Jun 2026 | 73.12 EUR | -2.6% | 71.05 EUR | 70.31 EUR | 0.88 | 3.26 | 30 | Off |
| 5 Jun 2026 | 75.08 EUR | 0.6% | 71.07 EUR | 70.38 EUR | 0.74 | 5.63 | 15 | Off |
| 29 May 2026 | 74.64 EUR | 2.4% | 70.96 EUR | 70.40 EUR | 0.47 | 3.73 | 719 | Off |
| 22 May 2026 | 72.92 EUR | 3.9% | 70.89 EUR | 70.43 EUR | 0.12 | 2.29 | 87 | Off |
| 15 May 2026 | 70.18 EUR | 1.8% | 70.66 EUR | 70.45 EUR | -0.21 | 2.40 | 31 | Off |
| 8 May 2026 | 68.94 EUR | -1.4% | 70.42 EUR | 70.52 EUR | -0.38 | -1.00 | 290 | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.